Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-ICG)
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-ICG) — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
About this event
CGA-IGC 2026 (Collaborative Group of the Americas on Inherited Gastrointestinal Cancer) — Event Research Description
Event: CGA-IGC 2026 – CGA-IGC 2026
Official title: The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) Annual Meeting
Dates (from official website): November 2–4, 2026
Location (from official website): Denver, Colorado, USA
Venue (from official website): Not explicitly stated in the provided website text (only “Denver” is confirmed).
About the event (what it is and why it matters)
CGA-IGC 2026 is described by the organizers as the 30th annual meeting and positioned as the “preeminent meeting for genetic counselors, physicians, scientists, advanced practice providers, trainees, and others involved in the diagnosis, treatment, and care of individuals with hereditary gastrointestinal cancer predisposition syndromes.” This framing indicates a clinically oriented, research-informed professional community with a strong focus on hereditary cancer risk, genetics-led care pathways, and translation of research into diagnosis and management.
The meeting is structured around an academic and professional program that includes elements such as an abstract process (including “browse abstract topics”), committee involvement, and support opportunities for sponsors/exhibitors. The audience therefore typically spans multiple roles: direct clinical care professionals, genetics counseling specialists, medical and scientific researchers, trainees, and allied healthcare stakeholders.
1) Who attends (BUYERS / ATTENDEES)
The official website specifically calls out the following attendee categories (buyer-relevant decision makers are typically concentrated among the clinician leadership and research/clinical operations roles, not only trainees):
- Genetic counselors
- Physicians involved in hereditary GI cancer care
- Scientists conducting hereditary cancer research and translational work
- Advanced practice providers
- Trainees (appearing as a named attendee group)
- “others involved” in diagnosis, treatment, and care of hereditary GI cancer predisposition syndromes
Buyer lens (buyer-relevant attendee types we would target): For attendee-list research and outreach, the strongest “buyer-like” roles in this domain usually include:
- Clinical leadership in hereditary cancer programs (e.g., hereditary cancer clinic directors, program directors)
- Genetic counseling leadership (e.g., genetic counseling program managers/directors)
- Clinical operations decision makers (e.g., administrators supporting cancer genetics services)
- Research operations stakeholders (e.g., clinical trial operations, research coordinators tied to genetics studies)
- Medical education / training leadership for programs that train genetic counselors and clinicians
- Partner stakeholders supporting diagnostics, testing workflows, and guideline-based care pathways
2) Where the show is happening + attendee geographic origin
Show location: Denver, Colorado, USA (confirmed by the official website content).
Venue: Not stated in the provided website text (we will keep venue unspecified unless you share the venue details from the official site pages such as “Venue” or the registration/hotel page).
Attendee geographic origin (reliability note): The official text confirms the organizer framing as “Collaborative Group of the Americas on Inherited Gastrointestinal Cancer,” which strongly implies cross-continental participation across the Americas (and often predominantly North America for in-person meetings of this type). However, the provided website content does not explicitly state: countries/cities of origin or a specific percentage split (local vs national vs international).
What we can confidently infer (without inventing numbers):
- Strong North America presence is likely given the event is hosted in the USA and explicitly references “Americas.”
- National U.S. pull is likely: genetic counselors and hereditary cancer specialists commonly travel across states for major professional genetic counseling and hereditary cancer conferences.
- Some international / cross-border presence may exist, but the official provided text does not confirm international attendee origin beyond the Americas umbrella.
If you want, we can refine geographic origin once you provide (a) the attendee demographics page, (b) the past attendee origin summary (if listed on the site), or (c) a sponsor prospectus that sometimes contains audience geography.
3) Audience reach (Local / National / Global)
Reach classification (based on official naming and positioning): National-to-regional within the Americas, with potential broader reach via participating international professionals.
The official description emphasizes a specialized professional community (“genetic counselors, physicians, scientists, advanced practice providers, trainees”) and positions the meeting as a leading forum for hereditary gastrointestinal cancer predisposition syndromes. These conferences typically attract a specialty network across:
- U.S.-based hereditary cancer programs
- Canadian and Latin American genetics/cancer professionals (plausible under “Americas” framing)
- Research groups and clinical trial networks active in hereditary cancer diagnostics and care pathways
Global reach: Not explicitly confirmed by the provided official text. Without additional official demographic statements, we keep “global” unconfirmed.
4) Sample buyer company names (BUYERS ONLY) + Websites
Because your request asks us to tailor buyer targeting to your client product requirements, we need your client’s website to accurately determine the best-fit buyer segment. Until we receive that, the table below focuses on high-fit buyer categories commonly associated with hereditary gastrointestinal cancer care ecosystems (e.g., genetic testing, precision medicine diagnostics support, cancer genetics support services, EHR/workflow and clinical informatics relevant to genetics-led care). We will refine and prioritize once you share the client website.
Please share your client website URL (the one you want buyers to match). Once we review it, we will re-rank and adjust the “Best Title to Target” and “Why This is a Good Buyer Fit” to align exactly with what we can reach through CGA-IGC 2026 attendee identities and roles.
Buyer-target samples (15–20 records)
| Priority | Company | Website | Best Title to Target | Why This is a Good Buyer Fit |
|---|---|---|---|---|
| 1 | Invitae | https://www.invitae.com | Head of Clinical Genomics / Medical Director, Genetic Testing | Hereditary GI cancer predisposition syndromes require strong clinical genomics leadership and medical oversight of genetic testing pathways. |
| 2 | Myriad Genetics | https://www.myriad.com | Vice President, Clinical Affairs / Medical Director, Hereditary Cancer Testing | Buyer relevance for hereditary cancer testing engagement, clinical evidence, and guideline-aligned adoption. |
| 3 | Ambry Genetics | https://www.ambrygen.com | Director, Clinical Genetics / Medical Affairs Lead, Hereditary Cancer | Specialty genetic testing organizations align closely with genetic counselor networks and hereditary GI cancer care delivery. |
| 4 | Foundation Medicine | https://www.foundationmedicine.com | Clinical Partnerships Director / Evidence & Outcomes Lead | Precision oncology and genomic testing evidence frameworks are often discussed in specialty hereditary cancer circles. |
| 5 | Guardant Health | https://guardanthealth.com | Director, Medical Affairs / Clinical Education Partnerships Lead | Hereditary cancer risk management may overlap with broader genomic approaches and clinical education initiatives. |
| 6 | Exact Sciences | https://www.exactsciences.com | Director, Clinical Affairs / Personalized Oncology Partnerships | Given GI cancer focus, organizations in GI diagnostics and clinical partnerships often seek connections with hereditary pathways specialists. |
| 7 | Freenome | https://www.freenome.com | Head of Clinical Partnerships / Medical Affairs Director | Early detection and cancer genomics platforms benefit from engagement with genetics-led hereditary cancer research communities. |
| 8 | Tempus | https://www.tempus.com | Director, Clinical Informatics Partnerships / Oncology Genomics Lead | Clinical informatics and evidence generation can attract hereditary cancer program leaders building data-driven care pathways. |
| 9 | DNAnexus | https://www.dnanexus.com | Head of Clinical Genomics Partnerships / Director, Healthcare Solutions | Genomics informatics infrastructure supports research and clinical workflows relevant to hereditary cancer syndromes. |
| 10 | Invitae (Genetic counseling support ecosystem partner model) | https://www.invitae.com | Director, Genetic Counseling Program Partnerships | Direct linkage between genetic testing services and the genetic counseling function that is explicitly named among primary attendees. |
| 11 | Strata Oncology | https://www.strataoncology.com | Director, Clinical Operations / Oncology Biomarker Programs | Models supporting clinical workflows and biomarker execution can fit the hereditary cancer testing journey. |
| 12 | Cancer Genetics services provider (Example: Color Health) | https://www.color.com | Head of Clinical Operations / Director, Medical Genetics | Population-facing genetic screening and genetic medicine delivery can align with hereditary cancer program interest (to be confirmed after product review). |
| 13 | Genoox / Precision medicine informatics (example: Genoox has varied offerings) | https://www.genoox.com | Partnerships Director / Healthcare Platform Lead | Hereditary cancer management frequently depends on actionable interpretation and workflow enablement—often supported by platform partners. |
| 14 | EPIC (health system informatics as a buyer category) | https://www.epic.com | Director, Clinical Decision Support / Genomics Workflow Lead | Large health system EHR ecosystem decisions may be relevant for genetics documentation and care pathway integration (title may vary by org). |
| 15 | Cerner / Oracle Health (buyer category) | https://www.oracle.com/health/ | Product Director, Population Health / Clinical Informatics Lead | Genetics documentation, clinical pathways, and follow-up scheduling can be supported by informatics vendors used by hereditary cancer programs. |
| 16 | Myriad Genetics (education & clinical affairs buyer category) | https://www.myriad.com | Senior Manager, Clinical Education / KOL Engagement Lead | Education and clinical evidence engagement is core to adoption among genetic counselors and physicians. |
| 17 | BluePrint Genetics (clinical testing buyer category) | https://www.blueprintgenetics.com | Director, Medical Affairs / Clinical Genomics Partnerships | Diagnostic genomics organizations can be a fit for hereditary GI cancer care collaboration. |
| 18 | CliniComp / specialty healthcare services (buyer category example) | https://www.clinilabs.com (note: verify exact brand for your needs) | Director, Specialty Operations / Clinical Services Partnerships | Specialty service organizations often engage genetics and oncology communities to improve testing operations and patient journey. |
| 19 | Roche (platform buyer category) | https://www.roche.com | Global Medical Affairs Lead / Oncology Diagnostics Partnerships | Large pharma/diagnostics groups frequently engage hereditary cancer communities through medical affairs and diagnostics partnerships. |
| 20 | Thermo Fisher Scientific (buyer category) | https://www.thermofisher.com | Director, Scientific Partnerships / Clinical Diagnostics Solutions Lead | Diagnostics and lab solutions can be relevant for genetic testing workflows and research enabling platforms. |
Important: The titles above are “best-fit targeting titles,” but actual job families will vary by company structure. Once we review your client product, we will (a) remove any low-fit entries, (b) re-prioritize the list, and (c) align titles precisely to your solution’s buyer decision makers.
5) Job profiles, industries & event type
Job profiles to target (high relevance to CGA-IGC 2026)
- Genetic Counseling Leadership: Director/Manager, Genetic Counseling; Program Director (Cancer Genetics)
- Clinical Leadership: Medical Director, Hereditary Cancer; Director, Gastrointestinal Cancer Program
- Medical Affairs / Clinical Affairs: Medical Affairs Director; Clinical Evidence Lead; Clinical Education lead
- Research leadership: Translational Research Director; Lab/Research Program Lead
- Advanced practice leadership: APP Program Lead (where applicable)
- Operations and pathway decision makers: Clinical Operations Manager; Cancer Program Operations Director
- Training and professional development: Education Lead; Workforce Development/Training Program leadership (if the client supports education resources or clinical training)
Industry alignment (based on your provided Apollo-style industry list)
Because the official event description is highly specialized within cancer genetics and hereditary disease diagnosis/care, the most relevant industry filters to use (from your Apollo-style list) are typically:
- Hospital & Health Care
- Medical Devices (where buyer solutions support clinical genetics workflows)
- Pharmaceuticals (medical affairs / precision oncology overlap)
- Biotechnology (genetic testing and clinical genomics)
- Information Technology & Services (clinical informatics, decision support, workflow integration)
- Research (translational and hereditary cancer research communities)
- Medical Practice (specialty clinical practice leadership)
- Health, Wellness & Fitness (only if the client targets patient support programs; lower priority than the categories above)
Event type classification
Event type: Medical / healthcare specialty conference, focused on genetic counseling, hereditary cancer diagnosis, treatment, and care pathways.
Primary domain: Hereditary gastrointestinal cancer predisposition syndromes.
6) Estimated attendance (expected total footfall)
The provided official website excerpt does not include an explicit attendance number (e.g., “expected attendees,” “registration count,” or “estimated attendance”). Therefore, we cannot reliably estimate total footfall from the provided text.
To complete this section accurately, we need one of the following from the official site or supporting materials:
- Any “At a Glance,” “Attendee Planning,” or event statistics section
- Past meeting attendance numbers (if listed)
- Sponsor prospectus / media kit with estimated attendance
For now, we will leave the attendance value as unconfirmed rather than guessing.
7) Key focus areas & buyer engagement
The official website “WELCOME MESSAGE” provides direct insight into the core themes: diagnosis, treatment, and care of individuals with hereditary gastrointestinal cancer predisposition syndromes.
Key focus areas (what buyers will care about)
- Genetic risk assessment and hereditary GI cancer predisposition syndromes
- Diagnosis and clinical decision support driven by genetic counseling workflows
- Treatment planning and care delivery for individuals with hereditary cancer risk
- Evidence sharing via abstracts and scientific programming
- Knowledge exchange among genetic counselors, physicians, scientists, and trainees
- Research-to-care translation (implied by the presence of scientists and the research-oriented meeting structure)
Buyer engagement angle (how we should position the outreach)
Since the meeting is inherently clinical and research-led, the engagement value for buyers typically increases when they can reach:
- Genetic counselors and cancer genetics clinic leaders who influence testing and care pathway decisions
- Medical directors and physicians who adopt evidence-backed hereditary cancer approaches
- Medical affairs and clinical evidence teams who want highly relevant professional exposure
- Research and translational leaders who seek collaboration and scientific visibility
Messaging that will resonate: “We can help you reach the hereditary gastrointestinal cancer and genetics-care decision-making community—genetic counseling leaders, hereditary cancer program physicians, clinical/scientific contributors, and program operations stakeholders attending CGA-IGC 2026.”
8) Client-product fit note (we need your client website)
We can provide the best buyers for CGA-IGC 2026 only after reviewing your client product requirements. Please share your client website URL so we can verify:
- Whether your client is a genetic testing / diagnostics solution, clinical informatics, education/training, patient support, biopharma support, or another category
- The most relevant buyer persona (clinical leadership vs medical affairs vs research operations vs program management)
- The best-fit industries from your Apollo-style industry list for attendee targeting
Once we have the client website, we will deliver:
- A re-ranked buyer company list (top 10–20) that best matches CGA-IGC 2026 attendee roles
- A refined set of “Best Title to Target” options per company type
- A tighter mapping to the most relevant industries from your provided industry list
9) Final recommendation (fit and next steps)
CGA-IGC 2026 is a strong niche event for any buyer whose product supports the hereditary gastrointestinal cancer care ecosystem—especially if the product intersects with genetics-led diagnosis, genetic counseling workflows, clinical evidence, and hereditary cancer program adoption.
What we need to produce the “best buyers” version: Please share your client website, and also confirm:
- Your primary buyer type (clinical leadership vs medical affairs vs lab/diagnostics vs informatics vs education)
- Whether you want buyers only from USA or from across the “Americas” community
- Any compliance-sensitive restrictions (e.g., roles you can/can’t contact)
After receiving the client website, we will update the buyer table to match your exact requirements and produce a final prioritized outreach-ready list for CGA-IGC 2026 attendees.
Quick reference summary (from official website extract)
- Event: CGA-IGC 2026 Annual Meeting
- Dates: November 2–4, 2026
- City/Country: Denver, Colorado, USA
- Core audience (stated): Genetic counselors, physicians, scientists, advanced practice providers, trainees, and others involved in hereditary GI cancer diagnosis/treatment/care
- Venue: Not explicitly provided in the excerpt (we will fill it once you confirm/allow us to use the “Venue” page content)
Data sheet
| Field | Details |
|---|---|
| Event Name | Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-ICG) 2026 Annual Meeting |
| Event Date | November 2–4, 2026 |
| Event Status | Upcoming |
| Venue | Not publicly confirmed on the copied official page content |
| City | Denver |
| State / Region | Colorado (CO) |
| Country | United States |
| Organizer | Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-ICG) |
| Official Event Website | cgaigcmeeting.org |
| Event Type | Annual scientific and professional meeting |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; Wellness, Health & Fitness |
| Audience Reach | National with international professional reach across the Americas |
| Estimated Attendance / Expected Footfall | Attendance figure not publicly confirmed by the organizer. |
| Attendance Data Reliability | Low for headcount; high for event purpose and audience type based on official meeting copy |
| Main Purpose of Event | Education, scientific exchange, abstract presentation, networking, and collaboration focused on inherited gastrointestinal cancer predisposition syndromes |
CGA-ICG 2026 is the 30th annual meeting of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. The official website describes it as the preeminent meeting for genetic counselors, physicians, scientists, advanced practice providers, trainees, and others involved in the diagnosis, treatment, and care of individuals with hereditary gastrointestinal cancer predisposition syndromes.
The event is highly relevant to the medical genetics, oncology, GI cancer research, and hereditary disease communities. It supports scientific learning, abstract submission, research discussion, professional development, and networking among clinicians, researchers, and care teams working in a specialized and clinically important segment of cancer genetics.
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Clinical genetics teams | Hospitals, academic medical centers, hereditary cancer clinics | Influence on testing pathways, clinical protocols, and vendor selection | High relevance for genetic testing, counseling tools, and clinical decision support |
| Physicians and gastroenterologists | GI practices, academic centers, cancer programs | Clinical decision-maker, referral influencer | Relevant for diagnostics, patient management solutions, and educational offerings |
| Oncologists | Cancer centers, oncology groups, hospital systems | Treatment pathway influence and referral integration | Relevant for hereditary cancer testing, biomarkers, and care coordination tools |
| Advanced practice providers | Hospital systems, specialty clinics | Care delivery and workflow adoption | Relevant for workflow software, patient education, and screening programs |
| Scientists and researchers | Universities, research institutes, labs, biotech groups | Research collaboration and technology evaluation | Relevant for sequencing, bioinformatics, lab platforms, and research services |
| Trainees and fellows | Medical schools, training hospitals, residency/fellowship programs | Future decision-makers and influencers | Useful for educational products, career development, and training subscriptions |
| Laboratory and molecular diagnostics leaders | Reference labs, academic labs, diagnostic companies | Technical evaluation and procurement influence | Relevant for testing platforms, workflow automation, and lab informatics |
| Healthcare administrators / program leaders | Cancer programs, health systems, specialty service lines | Budget oversight and service-line approval | Relevant for care pathway solutions, software, and program expansion services |
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Host city: Denver | Local and regional healthcare professionals, academic centers, and life science stakeholders | Medium | Convenient for Colorado-based medical and research organizations |
| Host state / region: Colorado and Mountain West | Regional hospitals, cancer centers, universities, and specialty clinics | Medium | Likely draw from surrounding states with genetics and oncology programs |
| Nearby business hubs | Denver-Boulder, Phoenix, Salt Lake City, Dallas, Chicago, Minneapolis, Seattle | Medium to High | These hubs contain academic medicine, hospitals, labs, and research buyers |
| National reach | U.S.-based genetics, oncology, GI, and pathology professionals | High | Official site positions the meeting as a professional annual gathering with broad clinical relevance |
| International reach | Americas-based scientific and clinical participants; potential global academic interest | Medium | Organizer branding references the Americas, indicating cross-border professional relevance |
| Reach Level | Assessment | Explanation |
|---|---|---|
| National | Primary classification | The event is based in the U.S. and appears to attract national clinical and research participation. |
| Global | Secondary reach description | Although not positioned as a mass global trade event, its scientific topic can attract international academic and medical interest. |
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| Mayo Clinic | Healthcare provider | Major academic medical center with genetics, oncology, and GI services | mayoclinic.org | Director of Genetics, Oncology Program Director, GI Service Line Leader | Strong Market Fit, Attendance Not Confirmed |
| Dana-Farber Cancer Institute | Cancer center | Relevant hereditary cancer and oncology decision-maker audience | dana-farber.org | Clinical Genetics Director, Oncology Operations Director, Research Manager | Strong Market Fit, Attendance Not Confirmed |
| Memorial Sloan Kettering Cancer Center | Cancer center | High-value hereditary cancer, GI oncology, and genetics audience | mskcc.org | Chief Medical Officer, Genetics Lead, Pathology Director | Strong Market Fit, Attendance Not Confirmed |
| MD Anderson Cancer Center | Cancer center | Large oncology system with hereditary cancer and GI experts | mdanderson.org | Clinical Operations Director, Genetics Program Leader, Research Director | Strong Market Fit, Attendance Not Confirmed |
| Cleveland Clinic | Healthcare provider | Multispecialty system with GI, cancer, and genetics leaders | clevelandclinic.org | Department Chair, Genetics Director, GI Division Head | Strong Market Fit, Attendance Not Confirmed |
| Johns Hopkins Medicine | Academic medical center | Research-heavy institution with GI cancer and genetics relevance | hopkinsmedicine.org | Medical Director, Research Program Manager, Clinical Genetics Lead | Strong Market Fit, Attendance Not Confirmed |
| Vanderbilt University Medical Center | Academic medical center | Relevant for inherited cancer, genetics, and GI care pathways | vumc.org | Program Director, Molecular Diagnostics Lead, Clinical Operations Manager | Strong Market Fit, Attendance Not Confirmed |
| University of Pennsylvania Health System | Academic health system | Genetics, oncology, pathology, and research decision-makers | pennmedicine.org | Clinical Director, Research Director, GI Oncology Lead | Strong Market Fit, Attendance Not Confirmed |
| National Cancer Institute | Government research organization | Federal cancer research and program leadership relevance | cancer.gov | Program Officer, Research Branch Chief, Clinical Trials Lead | Strong Market Fit, Attendance Not Confirmed |
| American Cancer Society | Nonprofit health organization | Cancer education, advocacy, and program partnerships | cancer.org | Program Director, Partnerships Director, Health Education Lead | Strong Market Fit, Attendance Not Confirmed |
| Ambry Genetics | Diagnostic genetics company | Genetic testing solutions align directly with meeting theme | ambrygen.com | Medical Affairs Director, Sales Director, Scientific Affairs Lead | Strong Market Fit, Attendance Not Confirmed |
| Invitae | Diagnostic genetics company | Hereditary cancer testing and provider education relevance | invitae.com | Provider Relations Director, Medical Science Liaison, Territory Manager | Strong Market Fit, Attendance Not Confirmed |
| Quest Diagnostics | Diagnostic laboratory | Lab testing, molecular diagnostics, and clinician outreach | questdiagnostics.com | Lab Director, Sales Executive, Medical Affairs Manager | Strong Market Fit, Attendance Not Confirmed |
| Labcorp | Diagnostic laboratory | Relevant lab services and hereditary cancer testing audience | labcorp.com | Business Development Director, Lab Operations Director, Clinical Liaison | Strong Market Fit, Attendance Not Confirmed |
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Medical Director, Genetics | Clinical / Genetics | Director to VP | Owns hereditary cancer pathways and vendor evaluation |
| 2 | Chief Medical Officer | Executive / Clinical | C-level | Influences institutional adoption and strategic partnerships |
| 3 | Director of Oncology Programs | Oncology | Director | Manages cancer care workflows and cross-department initiatives |
| 4 | GI Service Line Director | Gastroenterology | Director | Key for GI referral, screening, and hereditary risk workflows |
| 5 | Genetic Counselor | Genetics / Clinical | Individual contributor to manager | Core user of testing services, patient education, and referral tools |
| 6 | Research Director | Research | Director | Evaluates research collaborations, grants, and data platforms |
| 7 | Pathology Director | Pathology / Lab | Director | Influences diagnostic workflows and molecular test adoption |
| 8 | Clinical Operations Manager | Operations | Manager | Responsible for workflow efficiency and implementation |
| 9 | Medical Science Liaison | Medical Affairs | Mid to Senior | Supports scientific engagement and education |
| 10 | Program Manager, Hereditary Cancer | Cancer Programs | Manager | Coordinates screening, testing, and education initiatives |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Hospital & Health Care | Primary attendee base is clinical and hospital-based | Clinical decision-makers and service-line leaders |
| 2 | Biotechnology | Genetics and hereditary cancer technologies are biotech-adjacent | Medical affairs, business development, R&D |
| 3 | Medical Devices | Relevant for diagnostics and clinical workflow tools | Clinical adoption and procurement teams |
| 4 | Pharmaceuticals | Cancer therapeutics and precision medicine overlap | Medical affairs and strategic partnerships |
| 5 | Research | Scientific meeting centered on hereditary cancer research | Research collaborations and technology evaluation |
| 6 | Information Technology & Services | Clinical data, reporting, and registry systems are relevant | IT decision-makers and informatics buyers |
| 7 | Biotechnology Research | Strong fit for sequencing, biomarker, and translational work | R&D and translational science leaders |
| 8 | Medical Practice | Specialty clinical practices may attend for education and referral workflows | Practice owners and clinical leads |
| 9 | Higher Education | Academic medicine and research institutions are core attendees | Faculty, investigators, and training program leads |
| 10 | Government Administration | Public health and research organizations may participate | Program officers and policy leaders |
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | Not publicly confirmed | Unconfirmed | Official website copy reviewed | No organizer-published headcount visible in the provided content |
| Exhibitor count | Not publicly confirmed | Unconfirmed | Official website sections include Sponsorship & Exhibition, but no count provided | Scientific meeting likely has limited expo scale compared with large trade shows |
| Buyer count | Not publicly confirmed | Unconfirmed | Derived from attendee profile described by organizer | Buyer-side influence is present through clinical and research decision-makers |
| Speaker count | Not publicly confirmed | Unconfirmed | Agenda and program pages referenced by official site | No verified speaker count in the provided text |
| Sponsor count | Not publicly confirmed | Unconfirmed | Official site references confirmed supporters and support opportunities | Supporter list not included in the provided copy |
| Historical attendance | Not publicly confirmed | Unavailable | Previous annual meetings mentioned, but no figures included | Use as a specialized lead-source event rather than a high-volume attendee pool |
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Genetic testing | Accurate hereditary cancer testing and interpretation | Target genetics and oncology leaders with assay and workflow messaging | Testing services, NGS panels, variant interpretation, reporting platforms |
| Clinical education | Training for providers and counselors | Offer CME-adjacent content, education programs, and speaker support | Education services, training platforms, webinars |
| Research collaboration | Access to study partners and data-sharing opportunities | Engage investigators and lab leaders around collaborative studies | Research services, analytics, registry platforms, biobanking support |
| Care coordination | Referral management and patient navigation | Position software or services that improve hereditary cancer pathways | Patient navigation tools, care pathway software, CRM for clinics |
| Molecular diagnostics | Reliable lab outputs and faster turnaround times | Target lab directors and pathology stakeholders | Lab instruments, software, reagents, informatics, automation |
| Precision medicine | Integrating hereditary risk into personalized care | Frame solutions around patient stratification and clinical utility | Decision support, analytics, biomarker programs |
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | Very High | Attendees are directly involved in hereditary GI cancer diagnosis, treatment, and research. |
| Decision-maker availability | High | Likely includes directors, leads, faculty, and program owners rather than only entry-level attendees. |
| Data collection potential | Medium | Scientific meetings often publish agendas and speakers, but attendee lists may be limited. |
| Apollo targeting potential | High | Strong targeting by hospital, genetics, oncology, research, and lab titles is feasible. |
| Geographic targeting potential | High | Can target U.S. healthcare centers and Americas-based academic buyers. |
| Best outreach approach | Direct, educational, specialty-focused | Lead with hereditary cancer relevance, workflow improvement, and clinical/scientific value. |
| Overall lead quality | High | Strong specialist audience with meaningful buying influence and technical interest. |
| Best use case | B2B targeting, attendee list sales, sponsorship prospecting, and account-based outreach | Best suited for vendors selling to clinical genetics, oncology, labs, and research institutions. |
| Limitations / risks | Limited public attendee visibility | This is a specialized meeting; some audience data may only be available through registration or sponsorship materials. |
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Hospital & Health Care; Biotechnology; Medical Devices; Pharmaceuticals; Research; Information Technology & Services; Higher Education; Medical Practice; Government Administration; Nonprofit Organization Management | Covers the core attendee and buyer ecosystem |
| Departments | Clinical, Genetics, Oncology, Research, Medical Affairs, Operations, IT, Lab, Education | Targets actual users and internal decision-makers |
| Seniority | Manager, Director, VP, C-level, Head, Principal, Lead | Prioritizes decision-makers and budget owners |
| Job titles | Genetic Counselor, Clinical Geneticist, Oncology Director, GI Program Director, Lab Director, Research Director, Medical Affairs Director, Program Manager, Medical Director, Pathology Director | Matches the meeting’s highly specialized audience |
| Geography | United States; Canada; Mexico; Latin America; Americas | Aligns with the organizer’s regional scope |
| Employee size | 51-200; 201-500; 501-1,000; 1,001-5,000; 5,001-10,000; 10,000+ | Captures hospitals, labs, universities, and larger healthcare systems |
| Keywords | hereditary cancer, genetic counseling, GI cancer, colorectal cancer genetics, molecular diagnostics, cancer predisposition, Lynch syndrome, APC, BRCA, NGS, clinical genetics | Improves specialty relevance and list quality |
| Company type | Healthcare provider, academic institution, diagnostics lab, biotech, nonprofit, government research organization | Focuses on organizations most likely to buy or influence buying |
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| CGA-IGC 2026 official website | Official organizer source | Event name, dates, city, annual meeting purpose, audience description, and meeting structure | High |
| Official website page title and meta description | Official organizer source | Confirmed Denver, Colorado location and November 2–4, 2026 dates | High |
| Official website navigation items | Official organizer source | Presence of agenda, abstract, sponsorship/exhibition, attendee planning, hotel reservation, and venue sections | High |
| Welcome message on official website | Official organizer source | Attendee profile including genetic counselors, physicians, scientists, advanced practice providers, and trainees | High |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-ICG) — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.